The traditional view of Huntington's disease as a purely protein-driven degenerative process is being fundamentally challenged, with profound implications for how we approach treatment of this and dozens of related neurological conditions. Rather than focusing solely on toxic protein accumulation, emerging evidence points to ongoing DNA damage as the primary driver of disease progression.
Genome-wide studies have revealed that genetic variants in DNA repair pathways significantly influence when Huntington's symptoms begin and how rapidly they progress. The culprit appears to be somatic expansion of CAG repeats in affected brain tissues—the same DNA sequences that cause the disease continue expanding throughout a patient's lifetime, creating increasingly toxic huntingtin protein. This process occurs preferentially in the striatal neurons that die in Huntington's, suggesting the expansion itself drives neurodegeneration.
This DNA-centric model represents a paradigm shift with immediate therapeutic relevance. Currently, most Huntington's treatments focus on reducing huntingtin protein levels through gene silencing or other approaches. However, if somatic repeat expansion is the primary driver, interventions targeting DNA repair mechanisms could theoretically halt disease progression at its source. More intriguingly, such treatments might be effective across the entire spectrum of repeat expansion disorders, which includes over 45 conditions ranging from ALS to various ataxias.
The clinical implications are substantial but complex. Combination therapies targeting both DNA repair and protein reduction might prove more effective than either approach alone. However, determining optimal timing for intervention—before symptoms appear or after diagnosis—remains unclear, as does the question of whether halting DNA expansion can reverse existing neuronal damage or merely prevent further deterioration.